Billionaire John Paulson’s 5 Biggest Stock Picks

2. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Paulson’s Stake Value:$748.3 million

Percentage of John Paulson’s 13F Portfolio: 17.9%

Number of Hedge Fund Holders: 56

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is a biopharmaceutical company engaged in the research and development of medicines for rheumatic and rare diseases. It is ranked second on our list of billionaire John Paulson’s 10 biggest stock picks. The stock has returned over 41.32% to investors over the course of the past year.

The company posted its quarterly earnings report for the second quarter of 2021 on August 4, reporting earnings per share of $1.62, beating estimates by $0.75. The revenue over the period was around $833 million, up 79.90% year-over-year.

According to the recent 13F Filings, John Paulson’s Paulson & Co. held over 7.99 million shares of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), worth more than $748.3 million, accounting for 17.87% of the fund’s investment portfolio. At the end of the second quarter of 2021, 56 hedge funds in the database of Insider Monkey held stakes worth $4.3 billion in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). This is compared to 48 hedge funds in the previous quarter that held stakes worth roughly $4.1 billion.

On August 5, BMO Capital reiterated its Outperform rating on Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) and boosted its price target to $132 from $118, following the company’s strong second quarter results.

Carillon Tower Advisers, in their Q1 2021 investor letter, explains the position of  Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)’s Tepezza product. Here is what the fund said:

“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing of late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product Tepezza, which is used in the treatment of thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”